Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an announcement.
Livzon Pharmaceutical Group Inc. announced that its subsidiary, Livzon MABPharm Inc., has received acceptance from the National Medical Products Administration for the registration and market authorization application of its Recombinant Human Follitropin Alfa Solution for Injection. This step marks a significant advancement in the company’s product offerings in reproductive health, potentially strengthening its market position and providing new solutions for conditions such as anovulation and assisted reproductive technologies.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development, production, and distribution of a wide range of pharmaceutical products. It is involved in the production of therapeutic biological products, with a particular focus on reproductive health medications.
YTD Price Performance: -2.61%
Average Trading Volume: 3,997
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.04B
Learn more about 1513 stock on TipRanks’ Stock Analysis page.
